BSE · 524604
Adline Chem Lab Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -53.11% net margin, versus -271800% the period before.
Shareholding
As of 2026-06-30
- Promoter25.85%
- Public74.15%
18,444 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.38× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #41 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
| Adline Chem Lab Limited(this company) | ₹8 Cr | — | 0 | 15.84% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAdline Chem Lab Limited has a market capitalization of Rs 8 Cr. The company's book value per share is -Rs 3.03. Adline Chem Lab Limited has an EPS of 0 and a ROCE of -495.76%.
Positives
- +The company has a low debt-to-equity ratio of 0.
- +Promoter shareholding is not pledged, standing at 0%.
Negatives
- −The book value per share is negative at -Rs 3.03, indicating eroded shareholder equity.
- −Revenue has decreased significantly from Rs 6.330912 Cr in March 2021 to Rs 0.2489 Cr in March 2025.
- −The company has reported negative profit margins at 0%.
- −Return on capital employed (ROCE) is significantly negative at -495.76%.
- −The company is under GSM stage 2 surveillance.
Financial Performance
Adline Chem Lab Limited reported revenue of Rs 0.2489 Cr in March 2025. This marks a significant decrease from its revenue of Rs 6.330912 Cr in March 2021. The net profit was -Rs 0.1322 Cr in March 2025, following a net profit of Rs 0.717808 Cr in March 2022 and -Rs 4.234089 Cr in March 2023. Annual EPS has fluctuated significantly, from -Rs 2.19 in March 2021 to Rs 1.23 in March 2022, settling at -Rs 0.21 by March 2025.
Profitability & Returns
The company's return on capital employed (ROCE) stands at -495.76%, while the return on equity (ROE) is 15.84%. The profit margin is 0%. EBITDA has been negative for most of the reported periods, with -Rs 0.0449 Cr in March 2025 and a high of -Rs 1.251279 Cr in March 2021. The company's profitability has generally trended downwards in recent years, reflected in a negative EPS of -Rs 0.21 in March 2025.
Balance Sheet
Adline Chem Lab Limited has a debt-to-equity ratio of 0, indicating no debt reported. The book value per share is -Rs 3.03, indicating accumulated losses exceeding assets. The absence of debt reduces financial risk exposure from borrowed capital, but a negative book value indicates a weak financial position.
Ownership & Pledges
Promoter holding in Adline Chem Lab Limited is 25.8537% as of March 2026. Public shareholding is 74.1463%. There is no promoter pledging reported. Institutional holdings (DII and FII) are 0%. The number of shareholders is 18,446 as of March 2026.
Regulatory & Surveillance
Adline Chem Lab Limited is currently under GSM (Graded Surveillance Measure) Stage 2, which indicates heightened scrutiny from regulatory bodies. This measure is implemented on securities that witness an abnormal price rise not commensurate with the financial health and fundamentals of the company.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.